Headquartered in Hulsterweg 82, Venlo Fiscal year ends December NYSE: QGEN qiagen.com
QIAGEN N.V. is a global provider of Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples. The company's product portfolio spans sample technologies for isolating DNA, RNA and proteins; assay technologies for preparing biomolecules for analysis; bioinformatics for data interpretation; and automation solutions that integrate workflows. QIAGEN serves more than 500,000 customers worldwide across two main markets: Life Sciences (academia, pharma R&D, forensics, industrial applications) and Molecular Diagnostics (clinical healthcare). The company's key product groups include Sample technologies, Diagnostic solutions (including QuantiFERON for latent TB testing and QIAstat-Dx syndromic testing), PCR/Nucleic acid amplification (including QIAcuity digital PCR), and Genomics/NGS (including QIAGEN Digital Insights bioinformatics). QIAGEN operates as a single reportable segment with approximately 5,500 employees in over 35 locations worldwide. Recent acquisitions include Parse Biosciences (single-cell research solutions) and Genoox (AI-powered genomic data analysis). The company carries approximately $1.64 billion in total debt including convertible notes due 2027, 2031, and 2032, and German private placement bonds (Schuldschein) due through 2035. Updated
Pre-Market Stock Futures: Futures are trading lower after a mixed start to trading on Monday, following the holiday-shortened week due to the Juneteenth Federal holiday. We may start to see some end-of-the-quarter…
Pre-Market Stock Futures: The futures are trading mixed this morning, after what started as another week of the same old song and dance yesterday, before stocks turned around before noon, and it…
Wednesday's top analyst upgrades and downgrades included CVS Health, DataDog, Endeavor, Enphase Energy, Extreme Networks, GitLab, Nvidia, RTX, Splunk and United Parcel Service.
Tuesday's top analyst upgrades and downgrades included Alexion Pharmaceuticals, Bill.com, Boeing, Costco, Dicks Sporting Goods, Generac, Proofpoint, Regeneron Pharmaceuticals and Shopify.
Thursday's top analyst upgrades and downgrades included BioMarin Pharmaceuticals, Checkpoint Software Technologies, Cinemark, Fortinet, Palo Alto Networks, Regeneron Pharmaceuticals, Shake Shack, Ventas and Zscaler.
The top analyst upgrades, downgrades and initiations seen on Tuesday included AFL, Agilent, Allergan, Barrick Gold, Cognex, Hilton, Lloyds, MetLife, Slack and Wingstop.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
Thursday's top analyst upgrades, downgrades and initiations include AMAG Pharmaceuticals, Devon Energy, eBay, Freshpet, Range Resources, Raytheon, SeaWorld and Zynga.
A new report from Cowen makes the case that a blood test that detects evidence of cancer in the circulation could soon replace the older more traditional biopsy methods.
The following companies were featured in a new Leerink report on understand testing trends for sexually transmitted diseases.
U.S. equity markets opened slightly higher this morning following the report on U.S. jobless numbers (more coverage here). In Europe, the only data out today showed that U.K. retail sales fell 0.7%,…
Jon OggWhile investors generally see analysts issuing Buy ratings, it is always interesting to see what happens when Wall St. analysts give stocks to sell or when they have very cautious comments…
Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed very well…
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Monday. Apple Inc. (NASDAQ: AAPL) cut to Neutral and target cut to $575…
Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Wednesday morning. Amazon.com Inc. (NASDAQ: AMZN) Started as Neutral at Collins Stewart. Baidu,…
QIAGEN N.V. is a global provider of Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples.
24/7 Wall St.'s 12-month price target for QGEN is $53.07, rated Buy. The Wall Street consensus target is $46.27. QGEN price prediction →
